Philip Ashton-Rickardt

Philip Ashton-Rickardt

Directeur Technique/Scientifique/R&D chez SIGILON THERAPEUTICS, INC.
62 ans
Consumer Services
Health Technology

Profil

Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.

Postes actifs de Philip Ashton-Rickardt

SociétésPosteDébut
SIGILON THERAPEUTICS, INC. Directeur Technique/Scientifique/R&D 14/06/2021

Anciens postes connus de Philip Ashton-Rickardt

SociétésPosteFin
Corporate Officer/Principal 01/06/2021
Fondateur 31/10/2019
Corporate Officer/Principal 01/06/2006
Corporate Officer/Principal -
Voir l'expérience en détail de Philip Ashton-Rickardt

Formation de Philip Ashton-Rickardt

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

95

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées7

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Philip Ashton-Rickardt
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT
🔇